Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab.
Issue Date
2023-01-04Keywords
ACQASTHMA
biological therapy
exacerbation
real-word
Metadata
Show full item recordJournal
Frontiers in allergyDOI
10.3389/falgy.2022.1052339PubMed ID
36686966Item Type
ArticleLanguage
enEISSN
2673-6101ae974a485f413a2113503eed53cd6c53
10.3389/falgy.2022.1052339
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as © 2023 Walsh, Casey, Vairamani, Arnott, Plant and Murphy.
Related articles
- Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
- Authors: Scioscia G, Tondo P, Nolasco S, Pelaia C, Carpagnano GE, Caiaffa MF, Valenti G, Maglio A, Papia F, Triggiani M, Crimi N, Pelaia G, Vatrella A, Foschino Barbaro MP, Crimi C
- Issue date: 2023 Jun 28
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
- Authors: Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G
- Issue date: 2022 May
- A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
- Authors: Davison J, Doe S
- Issue date: 2021
- Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
- Authors: AlShareef S, McDonald CF, Lee J
- Issue date: 2022
- Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
- Authors: Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
- Issue date: 2021